Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 28K
2: EX-10.1 Material Contract HTML 71K
6: R1 Cover Page Cover Page HTML 45K
9: XML IDEA XML File -- Filing Summary XML 11K
7: XML XBRL Instance -- tndm-20230817_htm XML 13K
8: EXCEL IDEA Workbook of Financial Report Info XLSX 8K
4: EX-101.LAB XBRL Labels -- tndm-20230817_lab XML 67K
5: EX-101.PRE XBRL Presentations -- tndm-20230817_pre XML 33K
3: EX-101.SCH XBRL Schema -- tndm-20230817 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
11: ZIP XBRL Zipped Folder -- 0001438133-23-000179-xbrl Zip 28K
Registrant’s telephone number, including area code: (i858) i366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Each Exchange on Which Registered
iCommon Stock, par value $0.001 per share
iTNDM
iNasdaq
Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 17, 2023, Brian B. Hansen, Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the
Company), notified the Company of his decision to resign from his role as Executive Vice President and Chief Commercial Officer, effective December 31, 2023 (the Effective Date).
In connection with Mr. Hansen’s resignation, Mr. Hansen and the Company entered into a Separation Agreement on August 18, 2023, under which Mr. Hansen will remain employed with the Company until June 28, 2024 (the Separation Date), but will be on administrative leave after the Effective Date.
In addition to receiving his current base salary through the Separation Date, Mr. Hansen will be entitled to receive payment of a cash bonus award as determined based on the Company’s achievements under the previously filed 2023 Sr. Management Cash Bonus Plan, as well as COBRA premiums for up to six months following the Effective Date. In addition, equity awards held by Mr. Hansen as of the Effective Date will continue to vest through the Separation Date.
The foregoing summary of the Separation Agreement is not complete and is qualified in its entirety by reference to the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this report.
Cover Page Interactive Data File (embedded within the Inline XBRL document)
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
